Skip to content
PepGen Logo

PepGen: Q3 – Canadian Community Newsletter

October 20, 2023

PepGen has released its Q3 Canadian community newsletter that summarizes key Duchenne muscular dystrophy and DM1 updates, including details about their CONNECT clinical trials.

The CONNECT 1 and CONNECT 2 clinical studies are designed to evaluate the potential safety and efficacy of PGN-EDO51 in a broad population of boys and young men with DMD amenable to exon 51 skipping:

  • CONNECT1, our Canadian study, will be open for recruitment soon, and details of the study will be shared with the community.
  • Plans for CONNECT2, our global study, are ongoing.